Treatment method for relapsed/refractory disease needs to be made a decision based on prior therapy as well as The rationale why the initial cure was now not suitable (e.g., refractoriness vs. intolerance). Ibrutinib is the current gold common therapy for patients with relapsed/refractory sickness, determined by the outcome of a number of phase I-I